Acorda Therapeutics has enrolled the first patient in its second trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy. The first clinical trial with GGF2 provided initial data on tolerability and activity of a single infusion over a wide range of doses. That study also supported observations in preclinical models that GGF2 improved ...